
Just before the new year, the biotech company Ascendis Pharma applied to the US Food and Drug Administration for permission to start running trials with a drug candidate for the treatment of cancer, according a company announcement.
On previous occasions, the firm presented three possible cancer candidates, and the first to be put through a clinical trial program is Transcon TLR7/8 Agonist, which is designed to enhance the immune system by imitating the proteins TLR7 and TLR8.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app